Innate Pharma S.A. (IPHA) vs Satellos Bioscience (MSLE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Satellos Bioscience (MSLE) has outperformed Innate Pharma S.A. (IPHA) over the past year, gaining 7.4% versus a loss of 26.4%. Over five years, MSLE leads with a -50.8% price change compared with -74.8% for IPHA. Innate Pharma S.A. is the larger company by market cap ($165.3 million vs $155.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPHA | MSLE |
|---|---|---|
| Share price | $1.48 | $7.35 |
| Market cap | $165.32M | $155.83M |
| 1-day change | -2.63% | -3.74% |
| YTD return | -15.43% | +24.91% |
| 1-year return | -26.37% | +7.38% |
| 5-year return | -74.79% | -50.84% |
| EPS (TTM) | $-0.59 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.71 | $13.40 |
| 52-week low | $1.17 | $5.30 |
| Distance from 52-week high | -45.39% | -45.17% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +350.68% | +251.26% |
| Average volume | 156.96K | 50.10K |
| Shares outstanding | 111.70M | 21.22M |
| Employees | 120 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MSLE has outperformed IPHA by 33.8 percentage points over the past year.
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Healthcare · Biotechnology · 120 employees
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Healthcare · Biotechnology · 18 employees
IPHA vs MSLE FAQ
Which is bigger, Innate Pharma S.A. or Satellos Bioscience?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $165.32M compared with $155.83M for Satellos Bioscience (MSLE).
Which stock has performed better over the past year, IPHA or MSLE?
MSLE returned +7.38% over the past 12 months, compared with -26.37% for IPHA (price return, excluding dividends). Past performance does not predict future results.
Are Innate Pharma S.A. and Satellos Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.